Naperville, IL -- (SBWire) -- 11/08/2013 --Reportstack, provider of premium market research reports announces the addition of Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation market report to its offering
The leading business intelligence provider, has released its latest research “Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth” Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope

A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.

In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.

Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.

Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.

Discussion of the drivers and barriers for market growth or decay.

Reasons to Buy

Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.

Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.

Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.

Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

Related Industry Reports

Alzheimer’s Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff

Orphan Diseases Therapeutics in CNS to 2017-Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa,

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/145640/alzheimers-disease-therapeutics-market-to-2019-early-stage-innovation-points-to-disease-modifying-therapies-and-market-transformation.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###